好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Exploring DBS Outcomes in Dystonia
Movement Disorders
P8 - Poster Session 8 (5:30 PM-6:30 PM)
3-005
This study aims to explore factors that may contribute to the effectiveness of DBS in the treatment of dystonia.
Deep brain stimulation (DBS) effectively treats movement disorders when other
therapeutics become less effective in managing symptoms, but there can be heterogeneity of response based on several factors.
Demographic, genetic, and programming data from dystonia patients who underwent DBS at Mount Sinai Hospital (2011-2022) was collected through IRB-approved retrospective chart review when pre- and post- clinical rating scales were available. Patients were categorized based on post-DBS improvement [partial (<50% change) vs good (≥50%) change in BFMDRS or TWSTRS scores]. Total electrical energy delivered (TEED) was calculated using therapeutic impedance values or assumed to be 1000Ω when unavailable. Chi-squared, unpaired t-tests, Pearson’s correlation and ANOVA were performed to compare groups.  

N=17 patients with bilateral GPi DBS were included, 52.3% female, 76.5% >18 years (mean = 35.1 ± 18.1) and 70.6% Caucasian. Medications were significantly reduced after DBS (p<0.05). N=12 had a good and n=5 had partial improvement. All patients with DYT-1 dystonia (n=6) experienced good improvement. Disease duration at time of surgery correlated poorly with improvement (r=0.28 NS). There was no significant difference in TEED per hemisphere between the good and partial improvement groups (p=0.45). N=21 hemispheres were treated with high PW/low Freq, and the odds ratio of association with a good response was 1.11. N=6 hemispheres had high Freq/low PW paradigms, used significantly lower TEED, and all had a good response. Hemispheres with high PW/high Freq (n=7) used significantly higher TEED (p<0.001) with n=3 good and n=4 partial improvement.

Variation in dystonia DBS outcomes in a heterogeneous cohort do not appear to be strictly dependent on disease duration, genetics, or TEED.  Programming paradigms may be important and could indicate proximity to relevant circuitry and/or circuit characteristics, which may individually vary. 
Authors/Disclosures
Jaan Nandwani
PRESENTER 		Miss Nandwani has nothing to disclose.
Joan Miravite, DNP, RN, FNP-BC, FAAN, FAANP, DAAN (Mount Sinai West) Dr. Miravite has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Miravite has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Dr. Miravite has a non-compensated relationship as a Board Member with Association of Movement Disorder Advanced Practice Providers that is relevant to AAN interests or activities.
Winona W. Tse, MD (Mount sinai medical center) Dr. Tse has nothing to disclose.
Matthew Swan, MD, FAAN The institution of Dr. Swan has received research support from Biogen. The institution of Dr. Swan has received research support from Sage Therapeutics. The institution of Dr. Swan has received research support from Parkinson's Foundation. The institution of Dr. Swan has received research support from Photopharmics. The institution of Dr. Swan has received research support from Denali Therapeutics. The institution of Dr. Swan has received research support from NOEMA Pharma.
Naomi Lubarr, MD (Mount Sinai Beth Israel Medical Center) Dr. Lubarr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for applied therapeutics.
Brian Kopell No disclosure on file
Joohi Jimenez Shahed, MD, FAAN (Icahn School of Medicine at Mount Sinai) Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Treefrog. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RebrAIn. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BlueRock Therapeutics. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PhotoPharmics. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Emalex. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. The institution of Dr. Jimenez Shahed has received research support from Amneal. The institution of Dr. Jimenez Shahed has received research support from Annovis. The institution of Dr. Jimenez Shahed has received research support from SAGE. The institution of Dr. Jimenez Shahed has received research support from Ono Pharmaceuticals. The institution of Dr. Jimenez Shahed has received research support from BlueRock. The institution of Dr. Jimenez Shahed has received research support from Neuron23. Dr. Jimenez Shahed has received personal compensation in the range of $0-$499 for serving as a Faculty with Movement Disorders Society. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Faculty with 好色先生. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Parkinson Foundation.